A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.
End-stage diabetes mellitus is not a single organ failure — it is every system failing at once, after decades of trying to hold them together. What the hospice team needs to understand on day one.
End-stage diabetes mellitus is the terminal convergence of multiple organ system failures, each caused by decades of hyperglycemia-driven microvascular and macrovascular damage. The hospice patient with end-stage diabetes typically carries two or more simultaneous terminal complications: end-stage renal disease from diabetic nephropathy (apply the Card #47 dialysis framework — diabetic nephropathy is the leading single cause of ESRD in America); Class III–IV heart failure from diabetic cardiomyopathy and accelerated coronary artery disease; non-healing diabetic foot wounds with osteomyelitis and no surgical reconstruction option; bilateral major amputations with functional failure; severe autonomic neuropathy producing gastroparesis that causes malnutrition and renders oral medication delivery unreliable; and proliferative retinopathy with functional visual loss. The patient who arrives at hospice with all of these simultaneously has experienced what the diabetes community calls "multi-organ diabetic complications" — and has been grieving each loss incrementally for decades.[1]
The pathophysiology of end-stage diabetic complications converges on five mechanisms of hyperglycemia-induced cellular damage: oxidative stress from reactive oxygen species overproduction, advanced glycation end-product (AGE) accumulation in vascular walls and nerve tissue, polyol pathway overactivity depleting NADPH and producing osmotic stress in nerves and retinal cells, protein kinase C activation disrupting endothelial signaling, and hexosamine pathway activation altering gene expression in insulin-sensitive tissues. These mechanisms damage the endothelium and basement membrane of the microvasculature — producing the retinopathy, nephropathy, and neuropathy of microvascular disease — and accelerate atherogenesis in the coronary, cerebral, and peripheral arteries — producing the macrovascular disease cluster that kills most patients with end-stage diabetes through cardiovascular events rather than through glucose dysregulation.[5]
The two disease-specific clinical realities that define every hospice diabetes visit are the glucose management revolution and the pain crisis. At hospice enrollment, the decades-long project of HbA1c optimization must be replaced entirely by the single goal of avoiding hypoglycemia — a reframe that is clinically essential and emotionally difficult for patients who have organized their lives around glucose control. Simultaneously, painful diabetic peripheral neuropathy — the burning, shooting, electric shock pain that coexists with sensory loss in the same damaged nerves — is present in the majority of end-stage diabetes patients and has almost universally been undertreated. Prescribing combination gabapentinoid plus SNRI therapy from the first hospice visit, and establishing formal pre-procedure analgesia for every wound care dressing change, are the two clinical acts that most immediately improve quality of life at enrollment.[6]
End-stage diabetes is unique among hospice diagnoses in the duration and incrementalism of its devastation. Every other hospice diagnosis has a trajectory that can be measured in months to a few years. Diabetes destroys the body across decades — the toe, then the foot, then the leg; the vision in one eye, then the other; the kidney function that required dialysis; the cardiac function that required medication after medication. Each of these losses arrived without a defined mourning period, without clinical acknowledgment that it was a grief, without anyone saying "this loss deserves to be grieved." By the time the hospice clinician walks in, the patient has been grieving specific losses for so long that the grief has become structural. The clinician who asks "Can you tell me what the last ten years have been like — not just the medical history, but what it felt like to lose each of those things?" receives the most important contextual information of the entire enrollment and demonstrates that the accumulated story matters.
Diabetes is diagnosed before hospice enrollment. The hospice clinician's task is to construct a complete complication profile and translate the existing record into a hospice care plan. The complication inventory is the most important record review in end-stage diabetes.
Diabetic nephropathy: Most recent eGFR and trend; urine albumin-to-creatinine ratio (UACR) — above 300 mg/g indicates overt nephropathy. Dialysis status: if on dialysis, apply the Card #47 dialysis withdrawal framework. If ESRD without dialysis (conservative kidney management), apply Card #47 opioid safety requirements — morphine is contraindicated, fentanyl preferred.
Diabetic retinopathy: Most recent ophthalmology exam; stage (non-proliferative, proliferative, vitreous hemorrhage, traction retinal detachment); visual acuity and functional vision; visual aids in use. Blindness from diabetic retinopathy adds the functional dependencies of visual impairment — inability to read medication labels, draw insulin, or recognize hypoglycemia by visual inspection of skin color.
Peripheral neuropathy: Sensation testing by 10 g Semmes-Weinstein monofilament and 128 Hz tuning fork at enrollment visit; document absent sensation areas. Painful neuropathy assessment: burning, shooting, electric shock, allodynia. Current pain management and adequacy of neuropathic pain control.
Autonomic neuropathy: Orthostatic BP at 1 and 3 minutes after standing; gastroparesis history and treatment; bladder function (retention, frequency, urgency); cardiac autonomic neuropathy — resting tachycardia (HR above 100), reduced heart rate variability. Hypoglycemia unawareness assessment: does the patient notice symptoms when glucose falls below 70?
Your loved one's diabetes has affected many parts of the body over the years — the kidneys, the nerves, the blood vessels, the eyes, the heart. The hospice team's first job is to understand the full picture of which systems are affected and how severely, so we can focus our care on managing all of these complications together. You have been managing much of this alongside your loved one for years — you are a key part of the care team, and the information you provide about how things have been changing at home is as important as any lab result.
The pathophysiology of end-stage diabetic complications and the mechanisms behind the disease that arrived here. Relevant for family conversations, addressing self-blame, and understanding why these specific complications developed.
Type 2 diabetes begins with insulin resistance in peripheral tissues — skeletal muscle, liver, and adipose tissue — requiring compensatory pancreatic beta-cell hyperinsulinemia. Progressive beta-cell failure from glucotoxicity, lipotoxicity, and islet amyloid polypeptide deposition produces the eventual insulin deficiency that requires exogenous insulin therapy — a transition that often took years and was emotionally difficult for the patient.
Type 1 diabetes results from autoimmune beta-cell destruction — immune-mediated attack on pancreatic islets producing absolute insulin deficiency. The onset typically occurs in childhood or young adulthood. End-stage complications in type 1 diabetes typically emerge after 20–30 years of disease duration.
The most clinically counterintuitive feature of diabetic peripheral neuropathy is that sensory loss and neuropathic pain coexist in the same distribution. The same nerve damage that prevents the patient from feeling a wound developing in the foot also produces burning, shooting, electric shock sensations, and allodynia (pain from normally non-painful stimuli like bedsheets) in the same region. The mechanisms are distinct: the large-fiber neuropathy (damage to myelinated Aβ and Aα fibers) produces the numbness and proprioceptive loss — the inability to feel the wound. The small-fiber neuropathy (damage to unmyelinated C-fibers and thinly myelinated Aδ-fibers) and the central sensitization it produces generate the burning pain. The ectopic discharge of injured nociceptive neurons in dorsal root ganglia, and the loss of inhibitory interneurons in the spinal dorsal horn, maintain the pain state even as the sensory examination shows reduced or absent sensation. The patient who says "my feet are both numb and on fire" is not being contradictory — they are accurately describing two simultaneous but mechanistically distinct processes in the same damaged nerves.[7]
Type 2 diabetes is the most intensively framed-as-controllable disease in medicine. Your loved one was told from diagnosis that diet, exercise, and medication compliance would control it. The implicit — and sometimes explicit — message was that inadequate control reflects inadequate effort. The patient at end-stage who has multiple amputations and kidney failure has heard this message thousands of times and has likely internalized it as personal failure.
What is true: diabetes is driven by genetics, by biology, by social conditions that were not fully in anyone's control — the food environment that existed, the economic pressures, the healthcare access throughout a lifetime, the biology of beta-cell failure that accelerates independent of behavior. The disease that arrived here was not caused by insufficient willpower. It was caused by decades of physiological processes that are partially heritable and that respond only partially to behavior. The body was fighting this disease the entire time, and so was the person who lived in it.
Unlike many cancers, diabetes does not require germline mutation testing for family counseling purposes. However, first-degree relatives of patients with type 2 diabetes have 2–3× the general population risk of developing diabetes, and this information is clinically actionable — behavioral modification and metformin have both demonstrated prevention of diabetes conversion in high-risk relatives. For families present at hospice enrollment who are unaware of their own diabetes risk, a brief mention that diabetes has a significant hereditary component and that preventive screening is available is appropriate and potentially life-saving. For type 1 patients, first-degree relatives have approximately 5–10% lifetime risk of type 1 diabetes (versus 0.3% population risk) — HLA typing in high-risk relatives and TrialNet screening can identify those at highest risk.
Glucose management completely reframed. Hypoglycemia unawareness as the most dangerous acute complication. Diabetes medication deprescribing, wound care, amputation management, and gastroparesis — the clinical transformations that must happen at hospice enrollment.
The patient with end-stage diabetes has spent decades being counseled to keep HbA1c below 7–8%. This target was appropriate when preventing microvascular complications was clinically meaningful. At end-stage hospice with months of prognosis, the microvascular complications from hyperglycemia take 7–15 years to develop and are clinically irrelevant to the patient's remaining timeline.
The glucose target in end-stage diabetes hospice is singular: avoid symptomatic hypoglycemia. A glucose of 200 mg/dL is acceptable and requires no intervention. A glucose of 300 mg/dL may be acceptable if asymptomatic. The only dangerous glucose is the one that causes hypoglycemia — dizziness, diaphoresis, confusion, seizure, arrhythmia, loss of consciousness. Communicating this reframe to the patient and family is the most important glucose management conversation of the entire hospice enrollment. Write it down. Leave it in the home.
The patient with long-standing diabetes and cardiac autonomic neuropathy may have lost the adrenergic warning symptoms of hypoglycemia — sweating, tremor, palpitations, hunger — that normally alert a person to a falling glucose. In hypoglycemia unawareness, the glucose may fall to 40–50 mg/dL before the patient develops neuroglycopenic symptoms (confusion, slurred speech, seizure, loss of consciousness). The family who does not know to check glucose when the patient seems "off" or confused will misinterpret a hypoglycemic event as disease progression.
The non-healing diabetic foot wound in a patient with compromised peripheral circulation (TcPO2 below 20 mmHg, no bypass target, osteomyelitis) will not heal. The goal of wound care in this context is comfort, infection control, and odor management — not healing. This must be explicitly stated in the care plan and communicated to both the patient and family.
Diabetic gastroparesis results from vagal nerve damage producing delayed gastric emptying. Its clinical significance at hospice extends far beyond nausea and vomiting: the patient with severe gastroparesis who takes twelve medications by mouth twice daily is receiving pharmacologically unpredictable treatment. Assess oral medication absorption at every visit in patients with known or suspected gastroparesis.
Cardiovascular disease cluster: The cardiovascular disease driven by diabetes — coronary artery disease, diabetic cardiomyopathy, peripheral arterial disease, and cerebrovascular disease — causes 2–3 times as many deaths in diabetic patients as glucose dysregulation itself. At hospice, the Class III–IV heart failure patient from diabetic cardiomyopathy should be managed concurrently with the Card #33 (heart failure) framework. Cardiac autonomic neuropathy is clinically significant because it produces both the blunted heart rate response that creates hypoglycemia unawareness and the resting tachycardia that may mislead clinicians into overestimating cardiovascular reserve. The "silent MI" — the myocardial infarction that did not produce chest pain because the cardiac neuropathy took that sensation — is a known entity in long-standing diabetic patients; atypical presentations of ACS must be considered.[8]
Retinopathy and visual loss: Diabetic retinopathy is the leading cause of new blindness in working-age adults in the United States. The patient with functional visual loss from retinopathy requires a specific functional assessment at enrollment: Can they read medication labels? Can they draw up insulin? Can they recognize hypoglycemia by visual cues? Can they call for help? Blindness from diabetes adds sensory isolation to physical decline and increases fall risk, medication error risk, and emotional isolation. Assess for depression and social isolation specifically in patients with significant visual impairment.[9]
At end-stage diabetes, "therapy" means active symptom management — not disease reversal. These are the clinical criteria for interventions that remain meaningful at the hospice stage of this disease.
In end-stage diabetes hospice, the question "when does therapy make sense?" refers not to disease-directed therapy (which has been appropriately simplified or discontinued) but to the comfort-directed interventions that remain highly effective, the safety protocols that prevent acute harm, and the specific medical decisions that require active clinical judgment at each visit. The Diabetes UK / Joint British Diabetes Societies guidelines for end-of-life diabetes management explicitly endorse a simplified glucose management approach focused on symptom avoidance rather than HbA1c targets — the evidence base for this reframe is guideline-level.[10]
Specific thresholds for stopping diabetes therapies that are causing harm without benefit. The most dangerous medications in end-stage diabetes are not the comfort drugs — they are the disease-management drugs that continue past their clinical utility.
In end-stage diabetes, the therapies that "don't make sense" are predominantly the disease management interventions that have persisted past their clinical utility — not the comfort medications. The specific harm pattern in end-stage diabetes is that the aggressive glucose management that was once protective becomes acutely dangerous: the medications that lower blood sugar in a patient with hypoglycemia unawareness, unreliable oral intake, and ESRD are now capable of killing the patient faster than the disease itself. The clinician must hold this reversal clearly and act on it at the first visit.[12]
Some hospice patients arrive with diabetes that appears "well-controlled" by lab values — an HbA1c of 7.2% despite end-stage complications. This apparent control may be the result of the very hypoglycemia unawareness that makes the current regimen dangerous. A patient whose glucose fluctuates between 50 and 250 mg/dL without conscious awareness of the lows will have an averaged HbA1c that looks acceptable while experiencing life-threatening hypoglycemic episodes. Do not interpret a "good" HbA1c as evidence that the current regimen is safe. Ask about behavioral changes, unexplained confusion, and episodes where the patient was "found" unresponsive — these are the history items that reveal hypoglycemia unawareness, not the lab values.
Evidence-graded integrative, interventional, and complementary approaches for diabetic neuropathic pain, wound care pain, and functional quality of life. Grade A = RCT evidence; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Evidence grading, dosing where supported, and explicit safety assessment against the four simultaneous concerns of end-stage diabetes: hypoglycemia amplification, renal clearance, peripheral vascular effects, and gastroparesis absorption. Patients will use supplements — this section helps you have the right conversation.
End-stage diabetes creates a supplement safety landscape defined by four simultaneous concerns that are distinct in their combination:
The supplement that appears benign in a healthy adult with diabetes may be dangerous in an end-stage patient with ESRD, hypoglycemia unawareness, gastroparesis, and severe PAD simultaneously. Review every supplement against all four safety lenses.
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Safety in End-Stage Diabetes |
|---|---|---|---|---|
| Alpha-Lipoic Acid (ALA) | Grade B | 600 mg TID (ALADIN/SYDNEY-2 RCT dose); reduce to 600 mg daily in ESRD | Neuropathic pain reduction — antioxidant reducing oxidative stress-mediated nerve damage; ALADIN and SYDNEY-2 RCTs demonstrated significant pain score reduction in DPN; most evidence of any supplement for DPN pain | Hypoglycemia amplification risk: ALA has mild glucose-lowering properties through improved insulin sensitivity — monitor glucose when starting; reduce insulin dose preemptively. ESRD: reduce dose; renally cleared metabolites. Drug interaction: may enhance effect of insulin and sulfonylureas |
| Evening Primrose Oil | Grade B | 360–480 mg γ-linolenic acid (GLA) daily; 4–6 capsules of 500 mg oil | Neuropathic pain and nerve conduction — GLA (ω-6 PUFA) corrects the reduced GLA synthesis seen in diabetic nerves; multiple RCTs demonstrated improvement in nerve conduction velocity and neuropathic symptom scores; at least 6 months required for full effect | Anticoagulant interaction: GLA inhibits platelet aggregation — use caution if patient is on anticoagulation; not a contraindication but monitor for bleeding. Peripheral vascular: vasodilatory effects are generally favorable in DPN context. Gastroparesis: high-fat capsules may worsen gastric emptying delay — take with largest meal or consider liquid form |
| Vitamin B12 (Methylcobalamin) | Grade B | 500–1500 mcg daily oral (methylcobalamin preferred); 1000 mcg IM monthly if gastroparesis prevents absorption | Neuropathic symptoms in B12-deficient patients — particularly important because metformin use (common in diabetes history) causes B12 malabsorption over years; B12 deficiency neuropathy is mechanistically different from but clinically indistinguishable from DPN and is directly treatable; check B12 level at enrollment | ESRD: water-soluble, renally cleared; generally safe but monitor. Gastroparesis: oral absorption is unreliable — IM or sublingual route bypasses gastric absorption issues. Interaction: no significant drug interactions. Drug–nutrient interaction: metformin reduces B12 absorption; most hospice patients have had years of metformin use and should be presumed at risk for depletion |
| Magnesium (Glycinate or Citrate) | Grade C | 200–400 mg elemental magnesium daily; magnesium glycinate preferred for GI tolerability | Muscle cramps (especially nocturnal leg cramps common in DPN), neuropathic symptoms, and possible insulin sensitivity improvement; diabetic patients have higher rates of hypomagnesemia from urinary magnesium wasting driven by hyperglycemia; replacing magnesium may improve both cramping and glycemic stability | ESRD — significant concern: magnesium is renally excreted; accumulation in ESRD causes hypermagnesemia (bradycardia, hypotension, neuromuscular paralysis); contraindicated or restricted to very low doses in eGFR below 30; check serum magnesium before initiating. GI: oxide and sulfate forms cause diarrhea — use glycinate or citrate. Hypoglycemia: mild insulin-sensitizing effect; monitor glucose |
| Vitamin D3 | Grade C | 1000–2000 IU daily (check 25-OH vitamin D level first; supplement to achieve 30–50 ng/mL) | Neuropathic pain reduction — multiple observational studies link vitamin D deficiency to worse DPN pain scores; vitamin D deficiency is nearly universal in advanced ESRD; supplementation may improve neuropathic pain and mood; concurrent supplementation rationale is strong in a population where deficiency is the expected finding | ESRD — active vitamin D (calcitriol) used instead: patients on dialysis or advanced ESRD are typically already on calcitriol (activated vitamin D) prescribed by nephrology; confirm existing vitamin D management with nephrology before adding D3; vitamin D toxicity (hypercalcemia) is a risk in ESRD on activated vitamin D. Interaction: digoxin toxicity risk with hypercalcemia |
| Acetyl-L-Carnitine (ALCAR) | Grade C | 500–1000 mg TID; oral capsule | Neuropathic pain and nerve regeneration support — ALCAR supports mitochondrial function in neurons; multiple small RCTs demonstrated neuropathic pain reduction and electrophysiological improvement in DPN; proposed to support axonal regeneration through improved fatty acid metabolism in Schwann cells | ESRD: carnitine deficiency is common in ESRD; supplementation may actually be therapeutic — dialysis patients often receive IV carnitine; standard supplementation doses are likely safe but monitor for accumulation. Interaction: may enhance thyroid hormone effects. Gastroparesis: oral absorption variable — consider liquid form. Hypoglycemia: mild insulin-sensitizing effect reported; monitor glucose |
| Benfotiamine (Fat-Soluble B1) | Grade C | 150–300 mg twice daily | Neuropathic symptom reduction and AGE inhibition — fat-soluble thiamine analogue with superior bioavailability; reduces advanced glycation end-product (AGE) formation; multiple small European RCTs showed symptom improvement in DPN; mechanistically rational given the thiamine-dependent pathways in glucose metabolism that are disrupted by hyperglycemia | ESRD: generally considered safe; water-soluble thiamine metabolites; no significant accumulation reported. Interactions: minimal — one of the safest supplements in the diabetes polypharmacy context. Hypoglycemia: no significant glucose-lowering effect. Note: requires months of use; less evidence than ALA for acute pain relief |
| Coenzyme Q10 (CoQ10 / Ubiquinol) | Grade C | 100–200 mg daily with fatty meal (ubiquinol form preferred for absorption) | Mitochondrial support in neuropathy and heart failure — CoQ10 deficiency correlates with diabetic complication severity; statin use (common in diabetes history) depletes CoQ10; dual indication if statin has been recently deprescribed; some evidence for improvement in cardiac function in heart failure (with the caveats of limited statin benefit at hospice prognosis) | Anticoagulation interaction: CoQ10 has vitamin K-like structural similarity — may antagonize warfarin; check INR if patient is on warfarin. ESRD: fat-soluble; accumulation possible but not established as problematic. Gastroparesis: fat-soluble, requires dietary fat for absorption; absorption is particularly variable in gastroparesis |
A guide, not a prediction. End-stage diabetes is not a single disease trajectory — it is the simultaneous convergence of renal, cardiovascular, neurological, and vascular failure, each with its own natural history, each accelerating the others.
End-stage diabetes does not kill on a single trajectory. Three primary death pathways converge: ESRD terminal trajectory (the most common — apply the Card #47 dialysis withdrawal timeline for patients on or withdrawing from dialysis); cardiovascular terminal trajectory (the most acutely lethal — heart failure decompensation, arrhythmia from cardiac autonomic neuropathy, or sudden cardiac death from a silent MI that produced no chest pain because the neuropathy took that sensation too); and multi-system failure (the most gradual — weeks to months of progressive pulmonary, renal, and cardiac insufficiency converging). Use this timeline as a framework for anticipatory guidance, not as a prediction for any individual patient. The patient who arrives at hospice has already traveled the DECADES phase — the accumulated disease history is as clinically relevant as the current vital signs.[40]
End-stage diabetes pharmacology requires two simultaneous tasks: aggressive deprescribing of harmful diabetes medications and aggressive initiation of comfort medications that have almost certainly been absent.
Deprescribe immediately: Glyburide in any patient with eGFR below 60 (renally-cleared active metabolites cause fatal hypoglycemia — medication safety emergency equivalent to morphine in ESRD); Metformin in ESRD (lactic acidosis risk); GLP-1 agonists in gastroparesis (worsen gastric emptying dramatically); SGLT-2 inhibitors (genital infection risk, DKA risk without comfort benefit); mealtime bolus insulin in patients with gastroparesis or unreliable oral intake (hypoglycemia from timing mismatch); antihypertensives causing orthostatic hypotension (natural BP decline at end of life makes prior BP targets harmful).
Initiate immediately: Gabapentinoid + duloxetine combination for neuropathic pain (almost certainly undertreated); written pre-procedure opioid order for every dressing change (almost certainly absent); topical metronidazole for wound odor (almost certainly not prescribed); metoclopramide for gastroparesis (possibly present but undertreated). The opioid selection must reflect ESRD safety — fentanyl, not morphine, in any patient with eGFR below 30.[20]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Gabapentin | Anticonvulsant / Neuropathic pain (DPN) | 100–300 mg QHS; titrate q3 days | Backbone of DPN pain management. ESRD dose: 100 mg once daily, max 100 mg TID — normal renal function: 300–1200 mg TID. Monitor for sedation compounding uremic encephalopathy in ESRD. Start low, titrate every 3 days. Document renal dose adjustment explicitly.⚠ ESRD: severe accumulation — use Card #47 gabapentin dosing framework for eGFR below 30. Addresses both the central sensitization of DPN and, in concurrent fibrosis, the cough component. |
| Duloxetine | SNRI / Neuropathic pain + Depression | 30 mg daily × 2 wks, then 60 mg daily | FDA-approved for DPN. Targets descending noradrenergic inhibitory pathways — complementary mechanism to gabapentin. COMBO-DN trial: combination with pregabalin superior to monotherapy.[10] Addresses concurrent depression simultaneously. Titrate to 120 mg if 60 mg partially effective. ⚠ Avoid in eGFR below 30 — metabolite accumulation; use pregabalin or venlafaxine instead. |
| Pregabalin | Anticonvulsant / Neuropathic pain (DPN) | 25–75 mg BID; ESRD: 25 mg daily | Alternative to gabapentin — more predictable absorption, BID dosing. FDA-approved for DPN. Preferred in patients with gastroparesis (more reliable absorption than gabapentin due to different transport mechanism). ⚠ Renal dose adjustment required — ESRD maximum 25–50 mg/day.[12] |
| Fentanyl | Opioid / Wound pain + Severe neuropathic pain | 12.5–25 mcg/hr patch q72h; or 12.5–25 mcg SQ PRN | Preferred opioid in ESRD — hepatically metabolized to inactive metabolites; no renally-cleared active metabolites accumulating to cause CNS toxicity. Transdermal patch provides consistent analgesia for ongoing wound pain. SQ or IV for pre-procedure administration 30–45 minutes before dressing changes.[46] ⚠ Patch unreliable in severe cachexia or diaphoresis — use SQ infusion instead. |
| Hydromorphone | Opioid / Pain (moderate-severe) | 0.2–0.5 mg SQ q4h; titrate to comfort | Acceptable in mild-moderate CKD (eGFR 30–60); use with caution in ESRD — hydromorphone-3-glucuronide accumulates and may cause neuroexcitatory effects (myoclonus, agitation). Monitor closely if eGFR below 30. Preferred over morphine in all CKD stages. Useful for pre-procedure analgesia via SQ route. |
| Oxycodone | Opioid / Pain (non-ESRD patients) | 2.5–5 mg PO q4–6h PRN | Appropriate for neuropathic and wound pain in patients with eGFR above 30. Oxycodone RCT (Gimbel et al.) demonstrated efficacy for painful DPN.[16] For pre-procedure wound care analgesia, administer 30–45 minutes before dressing change. ⚠ Dose reduce 25–50% in eGFR 30–60; avoid in eGFR below 30 — use fentanyl instead. |
| Metoclopramide | Prokinetic / Gastroparesis, Nausea | 5–10 mg PO/SQ 30 min before meals | First-line prokinetic for diabetic gastroparesis. Improves gastric emptying and reduces nausea. Also available SQ for patients who cannot reliably absorb oral medications. Assess gastroparesis severity — if oral medications are not being absorbed, the route transition plan must begin.[31] ⚠ Maximum 12 weeks per FDA label due to tardive dyskinesia risk. EPS risk in elderly — monitor; reduce dose if tremor or rigidity appear. Contraindicated in suspected bowel obstruction. |
| Ondansetron | 5-HT3 antagonist / Nausea, Vomiting | 4–8 mg PO/SL/SQ q8h PRN | Adjunct antiemetic for gastroparesis-related nausea. Sublingual formulation useful in patients with severe gastroparesis who cannot reliably absorb oral forms. Safe in renal failure without dose adjustment. Use as scheduled antiemetic when metoclopramide insufficient or not tolerated. |
| Topical Lidocaine 5% | Topical analgesic / Focal neuropathic pain | 1–3 patches to painful area; 12h on / 12h off | Evidence-based for focal neuropathic pain from DPN — particularly allodynia (pain from light touch).[14] Apply to most painful area of foot/leg. Negligible systemic absorption. Can be combined with gabapentin + duloxetine for additive effect. Particularly valuable in allodynia where even bedsheet contact is painful. Safe in ESRD. |
| Topical Metronidazole | Topical antibiotic / Wound odor | 0.75% gel applied to wound bed at each dressing change | Comfort measure for anaerobic bacterial odor from non-healing diabetic foot wounds. Provides significant quality of life benefit for patient and family — wound odor is one of the most distressing non-pain symptoms in diabetic wound management. Apply directly to wound bed. Systemic absorption minimal.[36] Not for healing — for comfort. |
| Capsaicin 8% | TRPV1 agonist / Refractory neuropathic pain | Single 60-min application by trained provider; repeat q3 months PRN | High-concentration capsaicin patch for refractory painful DPN. STEP trial demonstrated significant pain reduction versus 0.04% control patch.[15] Applied in clinic setting by trained provider. Burning during application; pre-treat with topical lidocaine 30 min prior. Benefit for up to 3 months per application. Useful in patients with ESRD where systemic agents are dose-limited. |
| Midodrine | Alpha-1 agonist / Orthostatic hypotension | 2.5–10 mg PO TID (morning, midday, early afternoon — NOT evening) | For symptomatic orthostatic hypotension from diabetic autonomic neuropathy causing falls and syncope. Do not take after 6 PM — supine hypertension risk. Do not use in severe heart failure or ESRD with significant fluid retention. Measure orthostatic BPs before initiating and after first dose. |
| Fludrocortisone | Mineralocorticoid / Orthostatic hypotension | 0.05–0.2 mg PO daily | Increases intravascular volume to support standing BP in diabetic autonomic neuropathy. Use with caution in heart failure and ESRD — volume expansion can worsen congestion. Monitor electrolytes. Best for patients with relatively preserved cardiac and renal function who have disabling OH without fluid overload. |
| Mirtazapine | NaSSA antidepressant / Depression + Anorexia + Insomnia | 7.5–15 mg PO QHS | Addresses the triad of depression, anorexia, and insomnia simultaneously in a single agent. Particularly useful in patients with gastroparesis-related anorexia. Lower sedation at 7.5 mg than at higher doses (paradoxical sedation profile). Faster onset than SSRIs in hospice populations. Also addresses the neuropathic pain component via noradrenergic modulation.[50] |
| Insulin (basal simplified) | Hormone / Hypoglycemia prevention (not HbA1c targeting) | Reduce to 50% of prior basal dose; titrate to prevent symptomatic hypoglycemia only | Goal is hypoglycemia prevention, not glucose control. Reduce basal insulin to minimum required to prevent DKA (type 1) or symptomatic hyperglycemia (type 2). Stop ALL mealtime bolus insulin in patients with gastroparesis or unreliable oral intake — the timing mismatch causes dangerous hypoglycemia. A glucose of 200–300 mg/dL is acceptable. A glucose below 70 mg/dL with unawareness is a clinical emergency. Written glucose management plan must leave the home at first visit.[22] |
| Glucagon | Hormone / Severe hypoglycemia rescue | 1 mg IM/SQ PRN severe hypoglycemia (unconscious, cannot swallow) | For hypoglycemia unawareness patients or those at high fall/syncope risk from low glucose. Nasal glucagon (Baqsimi 3 mg intranasal) is easier for families to administer. Train the family at enrollment. Write it on the glucose management plan. The family who has not been trained on glucagon before the episode will call 911 instead of treating. Effectiveness reduced in ESRD with poor glycogen stores — oral glucose gel is preferred if patient has any swallowing. Nasal glucagon (Baqsimi) preferred for caregiver administration — no reconstitution required. |
| Oral glucose gel / Glucose tabs | Glucose source / Mild-moderate hypoglycemia | 15–20 g glucose PO; recheck in 15 min (rule of 15) | First-line for mild-moderate hypoglycemia in a patient who can swallow. Glucose gel tubes (15g each) placed at bedside and in every room of the home. Family instructed: any glucose below 70 mg/dL — give one tube, wait 15 minutes, recheck. Write this on the glucose management plan and leave it in the home. Do not use food — unreliable glucose content. Do not use orange juice in patients with ESRD — potassium load. |
| Lorazepam | Benzodiazepine / Anxiety + Terminal agitation | 0.5–1 mg PO/SQ q4–6h PRN | For anxiety from the accumulated psychosocial burden of end-stage diabetes, anticipatory grief, procedural anxiety before wound care, and terminal agitation. Scheduled dosing for severe anxiety. SQ route when oral absorption unreliable from gastroparesis. Useful pre-procedure (combined with opioid) in severe wound care anxiety.⚠ Accumulates in renal failure — reduce dose and frequency in ESRD; monitor for paradoxical agitation. |
| Midazolam | Benzodiazepine / Terminal agitation + Refractory symptoms | 2.5–5 mg SQ PRN; or 10–30 mg/24h SQ infusion | For terminal agitation, refractory dyspnea, and palliative sedation in refractory symptom burden. Have pre-drawn and labeled in comfort kit before active dying phase. ESRD patients may develop uremic agitation — midazolam is the preferred agent over haloperidol for severe agitation in this setting. Pre-draw 5 mg syringe and label at enrollment for patients approaching active dying phase. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h; or 0.6–1.2 mg/24h SQ infusion | Reduces terminal secretions (death rattle) without CNS penetration — preferred over hyoscine in patients who retain any level of consciousness. Safe in ESRD. Family education is essential: "The respiratory sound you hear is not distressing to your loved one — the noise sounds much worse than it feels." Begin when secretion sounds appear, not after family distress escalates. |
High-yield clinical pearls for the hospice team caring for patients with end-stage diabetes mellitus. The things that aren't in the textbook — learned at the bedside across thousands of visits with this population.
The psychological and spiritual weight of end-stage diabetes is unique — it is the grief of a disease that destroyed the body incrementally across decades while the patient was told they could have controlled it.
End-stage diabetes produces a psychosocial burden that is distinct from other terminal diagnoses in three important ways. First, the losses arrived incrementally across decades — not as a single catastrophic event — meaning the grief has accumulated over a lifetime without ever receiving a name, a ritual container, or a mourning period. Second, the disease has been framed as controllable throughout its entire course — the implicit and explicit message from the healthcare system has been that outcomes reflect patient effort — generating a specific self-blame burden that reaches its most acute expression at end stage. Third, the visible consequences — amputation, blindness, wound — are among the most physically and socially stigmatizing of any terminal illness, adding body image grief and social isolation to the clinical picture.[49]
The hospice social worker, chaplain, and clinician who understand these three dimensions provide psychosocial support that is specific, informed, and clinically meaningful — not generic grief counseling applied to a disease that needs specialized psychological attention.
End-stage diabetes is the most incrementally devastating disease in medicine. The toe, then the foot, then the leg. The vision in one eye, then the other. The kidney function that eventually required dialysis. The cardiac function that required medication adjustment. Each loss arrived without a defined mourning period, without the ritual container that death provides, without anyone in the clinical system saying "this is a loss and it deserves to be grieved." The patient who arrives at hospice has likely been grieving specific body parts, specific functional capacities, and specific life roles for years — sometimes decades — in silence.[49]
"Can you tell me about the losses you've had from this disease over the years — not just the medical history but what it felt like to lose each of those things?" — This question creates space for the accumulated grief narrative. Allow extended silence. The patient who begins crying before they finish the first sentence has been waiting for this question for years.
Type 2 diabetes is the most intensively framed-as-controllable disease in medicine. From diagnosis, the patient has heard repeatedly — from clinicians, dietitians, public health campaigns, and sometimes family members — that diet, exercise, and medication compliance control the disease. The implicit and sometimes explicit message is that inadequate control reflects inadequate effort. The patient who arrives at end stage with multiple amputations and ESRD has heard this message thousands of times and has likely internalized it as personal failure.[52]
"I want to say something about the idea that you could have controlled this better. Diabetes is driven by genetics, by biology, by the conditions you lived in — the food environment, the economic pressures, the healthcare access you had throughout your life. The disease that brought you here is not the result of personal failure. It is the result of a biological process that medicine has not been able to stop, and social conditions that made it much harder. The complications you have are the result of the disease — not the result of what you did or didn't do well enough."
Major lower extremity amputation produces a body image grief that is specific, intense, and often unaddressed by clinical teams who focus on wound healing and rehabilitation rather than the psychological experience of living in an altered body. At hospice, where rehabilitation is no longer the goal, the amputation grief has nowhere to go unless the clinical team creates space for it. The patient who had a below-knee amputation two years ago and a contralateral above-knee amputation six months ago is carrying two separate grief processes simultaneously — each at a different stage, each with its own meaning.[51]
Home wound care for diabetic foot ulcers is among the highest-burden caregiving tasks in hospice — technically demanding, emotionally distressing, and physically taxing, performed daily or twice daily by family members who received a 30-minute wound care teaching and then were expected to manage a complex, malodorous, painful procedure indefinitely. Caregiver burnout rates in chronic wound management are high, and the hospice caregiver managing a diabetic foot wound is at particular risk.[52]
PHQ-2: "Over the past two weeks, have you had little interest or pleasure in doing things?" + "Have you been feeling down, hopeless, or depressed?" Score ≥3 warrants PHQ-9.[49]
Plain language for families caring for a loved one with end-stage diabetes. Share, print, or read aloud at the bedside.
Your loved one has spent years — maybe decades — managing diabetes and watching it take things away, piece by piece. Now the goal of their care has shifted from managing the disease to managing their comfort. That means some things you've done for years to keep them healthy — chasing blood sugar numbers, giving mealtime insulin, watching every bite they eat — have changed. Your hospice team is here to guide you through what matters now. The most important thing to know: a high blood sugar number is no longer the emergency. A low blood sugar is. This guide explains what you may see, what you can do, and exactly when to call us.
Próximamente en español. — Coming soon in Spanish.
The goal of blood sugar management has completely changed. For years, the goal was keeping blood sugar as low as possible. Now the goal is the opposite: prevent LOW blood sugar. A blood sugar of 200 or even 300 is acceptable now — it does not need a medication adjustment. A blood sugar below 70 is dangerous and needs immediate action. Your nurse will give you a written plan — keep it on the counter where everyone can see it.
Blood sugar below 70 mg/dL (especially if your person is confused or hard to wake) — give glucose gel if they can swallow; nasal glucagon if they cannot; call immediately. Blood sugar above 400 mg/dL with symptoms such as vomiting or severe confusion. Vomiting of medications — your person cannot keep their medications down and may not be getting their pain or comfort medication. Severe burning or electrical pain in the feet or legs that the current medication is not managing. Sudden confusion or change in responsiveness — always check glucose first, then call. Fall or injury during a position change. Wound dressing change producing severe pain despite the pre-medication — the pre-procedure medication dose may need to be increased. Wound odor that has suddenly changed or worsened — this may indicate an infection requiring assessment. Breathing that is very labored, or lips or fingernails turning blue or gray. Any time you are worried or unsure — call. That is what we are here for.
🙏 Your presence through every dressing change, every difficult night, every glucose check at 3 AM is an act of love as clinical as any medication. The person you are caring for has managed this disease for decades — they have carried a heavy weight for a very long time. What you are giving them now is the chance to put that weight down, with someone they love beside them. That matters more than any number on a glucose meter.
Twelve years at the bedside with end-stage diabetes. What I've learned, what I wish I'd known sooner, and what I tell every nurse on their first diabetes case. Not guidelines — real.
Peer-reviewed citations organized by clinical category. PMIDs hyperlinked. Evidence levels assigned by article type.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed and evidence-based clinical guidelines. © Terminal2 | terminal2.care
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.